Deterministic Size-Based Cell Separation outperforming the competition.
Tony Ward, Curate Biosciences CTO, discusses the value of using Determinist Size-Based Cell Separation to improve Cell Therapy Manufacturing starting material quality and quantity.
lnkd.in/ggHubXrH
What's happening with the fastest microfluidics cell separator in the world. Join our CBO Gaurav Vij at #BIO2022 on June 15 at 3:30pm to learn more about Curate Biosciences' business and pipeline development plans.
Or, schedule a meeting with us: ow.ly/oAFu50JnLnE
Hear more about our business and pipeline development at #BIO2022 San Diego. Our CBO Gaurav Vij will share updates on June 15th at 3:30pm. If you would like to learn more, send us a meeting request on the partnering portal: ow.ly/oAFu50JnLnE#celltherapy
Thanks to everyone at #ISCT2022 who highlighted the "magic" of the Curate Cell Processing System for improving cell therapy manufacturing starting material. Thanks to @ISCTglobal.
View our presentation on size-based Determinist Cell Separation: ow.ly/suYm50J6Cyk
#ISCT2022 in full swing. Exciting seeing all the interest in our Curate Cell Processing System. If at ISCT, stop by @curatebio booth 709 to learn more about the advantages of our label-free, size-based Deterministic Cell Separation technology.
...ask us how fast and easy it is.
Learn more about how our Curate Cell Processing System can dramatically improve cell therapy manufacturing starting material quality and quantity. Our CTO Tony Ward is presenting at #ISCT22 today at 4:15pm in Global Showcase Theater 2 in the Exhibit hall.
ow.ly/FqXA50J0rYU
How is DCS Technology different (and better) than other methods, such as density centrifugation, counterflow centrifugation and spinning membrane filtration?
See how DCS technology works: ow.ly/wrhk50IY7Cg
The race to make dose starts here!
The Curate® Cell Processing System is designed to help dramatically shorten the manufacturing time for next-generation cell therapies. Learn more about our technology: ow.ly/PYoT50IXi9w#cellandgene#celltherapy#Cancer
Biopharma Reporter interviews Curate Biosciences Senior Vice President Joan Haab, PhD. on @cityofhope's plan to use the Curate Cell Processing system to manufacture an investigational CAR-T cell therapy to attack HIV
#celltherapy#biopharma#HIVbiopharma-reporter.com/Artic…
GPB Scientific announces additional $18M financing:
We are pleased to see that our progress over the past year has been recognized by our existing partners and by new, important sponsors that share our vision for advancing therapies businesswire.com/news/home/2…